Krebs Biochemicals & Industries Ltd

As of 12-Nov, Krebs Biochemicals & Industries Ltd's stock price is Rs 66.89, down 4.36%, significantly underperforming its sector and the broader market. The stock has seen a substantial decline over the past week and year, with a sharp drop in investor participation, indicating a bearish trend and lack of confidence.

Krebs Biochem has experienced declining net sales and increasing losses, with total operating income falling from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25, and negative operating profit worsening from -33.99 Cr to -14.32 Cr during the same period. The company's financial health is further indicated by rising total liabilities and deteriorating shareholder equity, resulting in ongoing financial challenges.

Krebs Biochemicals' latest Q2 FY26 results are poor, showing a 67.57% year-on-year revenue decline to ₹4.17 crores, a net loss of ₹6.14 crores, and a negative book value, indicating significant operational and financial challenges.

As of 13-Oct, Krebs Biochemicals & Industries Ltd's stock price is Rs 70.55, down 2.22%, with significant volatility and a sharp decline in investor participation. The stock has underperformed the Sensex over various time frames, contributing to its recent decline.

As of 08-Oct, Krebs Biochemicals & Industries Ltd is seeing a price increase to Rs 75.93, up 5.17% today, but has a year-to-date decline of 17.91% and shows signs of volatility and decreased investor participation. Despite recent short-term gains, the stock's long-term performance remains weak compared to the broader market.

As of 26-Sep, Krebs Biochemicals & Industries Ltd's stock price is Rs 70.50, down 4.91%, with a total loss of 12.96% over the last three days. The company has reported negative results for three consecutive quarters, has a negative book value, and has significantly underperformed the market, contributing to investor skepticism.

As of 24-Sep, Krebs Biochemicals & Industries Ltd is facing a significant decline in stock price, currently at 76.95, down 5.0%, and has underperformed its sector by 99.55%. The company has reported negative results for three consecutive quarters, leading to a strong sell recommendation due to weak fundamentals and bearish trends.

As of 23-Sep, Krebs Biochemicals & Industries Ltd's stock price is at 77.70, down 2.83%, with significant declines in delivery volume and long-term performance, including a 32.14% drop over three years. The company's weak financials and negative results over the last three quarters indicate it is a risky investment compared to its historical valuations.

As of 22-Sep, Krebs Biochemicals & Industries Ltd is seeing a short-term price increase to Rs 81.00, but faces significant long-term challenges, including negative book value and declining sales. Despite outperforming the sector recently, its overall fundamentals indicate a risky investment environment.

As of 19-Sep, Krebs Biochemicals & Industries Ltd's stock price is declining at 77.65, down 0.65% today and 16.05% year-to-date, significantly underperforming the Sensex. The stock shows a bearish trend with a drastic decrease in delivery volume and no identified catalysts for recovery.

As of 18-Sep, Krebs Biochemicals & Industries Ltd's stock price is Rs 78.16, down 3.51%, and has underperformed its sector. Despite a significant increase in delivery volume, the stock remains below key moving averages and has declined 15.50% year-to-date, indicating a bearish trend and waning investor confidence.

As of 17-Sep, Krebs Biochemicals & Industries Ltd is currently priced at Rs 81.00, reflecting a recent upward trend with an 8% gain over two days and significant investor interest. Despite this short-term performance, the stock has a negative year-to-date return of -12.43% and has struggled over the longer term.

As of 16-Sep, Krebs Biochemicals & Industries Ltd is seeing a price increase to Rs 78.75, up 5.0% today and 8.47% over the past week, although it remains down 14.86% year-to-date. The stock is outperforming its sector and the broader market recently, but has significantly underperformed over longer periods.

Krebs Biochemicals & Industries Ltd is experiencing heightened buying activity, with a notable rise today and a strong weekly performance. Despite recent gains, the stock faces longer-term challenges, showing declines over the past three months and year-to-date. Current momentum may be influenced by market sentiment and sector developments.

Krebs Biochemicals & Industries Ltd experienced significant trading activity today, with its stock reaching the upper circuit limit and an intraday high of Rs 78.46. The company showed a trend reversal after two days of decline, with increased investor participation and notable performance relative to its sector.

As of 15-Sep, Krebs Biochemicals & Industries Ltd's stock price is Rs 75.00, down 2.93%, reflecting significant underperformance with a year-to-date decline of 18.92% and a 38.78% drop over three years, amid negative financial results and high debt levels. The stock's weak trading activity and declining investor participation further highlight its challenges in the market.